EpimAb Biotherapeutics, Inc.

One key indicator of the health of the biopharma industry is the rate of new company creation, and a new Evaluate analysis, using series A financings as a proxy shows that 2024 saw an encouraging up

A key indicator of the strength of the biopharma industry is the health of new company creation. By reviewing Series A financing announced in 2024 as a proxy, In Vivo once again takes measurement of

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Merck Obtains Global Rights To Hansoh’

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Vignette Gets Rights To BCMA×CD3 Bispec